{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:21:03Z","timestamp":1791580863226,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106886","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:46:28Z","timestamp":1764089188000},"page":"106886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-4001","authenticated-orcid":false,"given":"Stephen L.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Abeyewickreme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseanne","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106886_bib0001","doi-asserted-by":"crossref","DOI":"10.1186\/s41983-021-00383-4","article-title":"Assessment of cognitive functions in patients with multiple sclerosis","volume":"57","author":"Al-Falaki","year":"2021","journal-title":"Egypt J. Neurol. Psychiatry Neurosurg."},{"issue":"6","key":"10.1016\/j.msard.2025.106886_bib0002","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106886_bib0003","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7224\/1537-2073.2018-087","article-title":"Effect of multiple sclerosis on daily activities, emotional well-being, and relationships: the global vsMS survey","volume":"22","author":"Bass","year":"2020","journal-title":"Int. J. MS. Care"},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2025.106886_bib0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106886_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.msard.2025.106886_bib0007","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106886_bib0008","series-title":"Enhanced Safety Profile of Ocrelizumab Over Rituximab in Multiple Sclerosis treatment. P432","author":"Cerono","year":"2025"},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0009","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106886_bib0010","series-title":"Paper presented at the CMSC Annual Meeting 2023","article-title":"Five-year safety of ofatumumab in people living with relapsing multiple sclerosis","author":"Cohen","year":"2023"},{"issue":"13","key":"10.1016\/j.msard.2025.106886_bib0011","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1177\/1352458520988637","article-title":"Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation","volume":"27","author":"Dahlke","year":"2021","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106886_bib0012","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106886_bib0013","unstructured":"European Medicines Agency (2021). \"Kesimpta (ofatumumab). EU summary of product characteristics. 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed December 2024.\"."},{"issue":"12","key":"10.1016\/j.msard.2025.106886_bib0014","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-naive individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.msard.2025.106886_bib0015","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/s41591-025-03901-6","article-title":"AI-driven reclassification of multiple sclerosis progression","volume":"31","author":"Ganjgahi","year":"2025","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106886_bib0016","article-title":"Relapse rate and MRI activity in young adult patients with multiple sclerosis: a post hoc analysis of phase 3 fingolimod trials","volume":"4","author":"Gartner","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.msard.2025.106886_bib0017","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2025.106886_bib0018","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106886_bib0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2025.106886_bib0021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106886_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis","author":"Hauser","year":"2025","journal-title":"Neurol. Therapy"},{"issue":"10","key":"10.1016\/j.msard.2025.106886_bib0023","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0024","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol. Ther."},{"issue":"11\u201312","key":"10.1016\/j.msard.2025.106886_bib0025","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106886_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"suppl 1","key":"10.1016\/j.msard.2025.106886_bib0027","first-page":"185","article-title":"Five-year efficacy outcomes of ofatumumab in relapsing MS patients: insights from ALITHIOS open-label extension study","volume":"30","author":"Kappos","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106886_bib0028","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585211055934","article-title":"Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study","volume":"28","author":"Kira","year":"2022","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2025.106886_bib0029","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.msard.2025.106886_bib0030","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1007\/s10072-021-05165-7","article-title":"Cognitive impairment in multiple sclerosis: diagnosis and monitoring","volume":"42","author":"Meca-Lallana","year":"2021","journal-title":"Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106886_bib0031","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/13854046.2010.511272","article-title":"Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline","volume":"24","author":"Morrow","year":"2010","journal-title":"Clin. Neuropsychol."},{"issue":"11","key":"10.1016\/j.msard.2025.106886_bib0032","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/1352458510378021","article-title":"Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks","volume":"16","author":"Morrow","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106886_bib0033","unstructured":"Novartis Pharma AG \"Data on file. Periodic Safety Update Report (Cut-off date: 25 September 2024); Novartis Pharma AG.\"."},{"key":"10.1016\/j.msard.2025.106886_bib0034","unstructured":"Novartis Pharmaceuticals Corporation. 2024. Kesimpta\u00ae six-year efficacy data show substantial benefits in recently diagnosed treatment naive people with relapsing multiple sclerosis. Available at: https:\/\/www.novartis.com\/us-en\/news\/media-releases\/novartis-kesimpta-six-year-efficacy-data-show-substantial-benefits-recently-diagnosed-treatment-naive-people-relapsing-multiple-sclerosis."},{"key":"10.1016\/j.msard.2025.106886_bib0035","unstructured":"Novartis Pharmaceuticals Corporation (2020). \"Kesimpta (ofatumumab) injection, for subcutaneous use: US prescribing information. 2020. Available at: https:\/\/www.hcp.novartis.com\/products\/kesimpta\/rms. Accessed December 2024.\"."},{"issue":"6","key":"10.1016\/j.msard.2025.106886_bib0036","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106886_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106886_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105751","article-title":"Real-world evidence from Germany and the United States: treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis","volume":"88","author":"Papukchieva","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106886_bib0039","series-title":"Longer-Term (up to 6 Years) Efficacy of Ofatumumab in People With Recently Diagnosed and Treatment-Naive Relapsing Multiple Sclerosis","author":"Pardo","year":"2024"},{"issue":"12","key":"10.1016\/j.msard.2025.106886_bib0040","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0041","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0042","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106886_bib0043","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106886_bib0044","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","article-title":"Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"44","author":"Saidha","year":"2023","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106886_bib0045","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","article-title":"Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption","volume":"271","author":"Singer","year":"2024","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106886_bib0046","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106886_bib0047","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2025.106886_bib0048","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","article-title":"Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve","volume":"11","author":"Vollmer","year":"2021","journal-title":"Neurol. Clin. Pract."},{"issue":"7","key":"10.1016\/j.msard.2025.106886_bib0049","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/13524585211049397","article-title":"Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology","volume":"28","author":"Weinstock","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106886_bib0050","series-title":"9th Joint ECTRIMS-ACTRIMS Meeting","article-title":"COVID-19 outcomes and seropositivity rates following SARS-CoV-2 vaccine and\/or infection in ofatumumab-treated RMS patients: data from the ALITHIOS open-label extension study","author":"Wiendl","year":"2023"},{"key":"10.1016\/j.msard.2025.106886_bib0051","series-title":"Longer-Term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6 Years","author":"Wiendl","year":"2024"},{"key":"10.1016\/j.msard.2025.106886_bib0052","unstructured":"World Health Organisation. (2025). \"WHO COVID-19 dashboard.\" Retrieved 30 May 2025, from https:\/\/data.who.int\/dashboards\/covid19\/cases."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:29:44Z","timestamp":1781076584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S2211034825006248"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106886","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106886"}}